Atle Fund Management AB portfolio
Concentrated managerType not verifiedPortfolio as of Jun 30, 2026 (Q2 2026) · filed with the SEC on Jul 24, 2026 · data updated on Nov 5, 2026 · Q2 2026 13F (filing) ↗ · all its 13F filings ↗
A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.
The Q3 2025 13F filing also has internal inconsistencies and is not included in totals.
Atle Fund Management AB reported a $372M portfolio of 39 positions to the SEC as of the end of Q2 2026. Its largest positions are LLY, MRK, JNJ. During the quarter it opened Biogen and Oruka Therapeutics and exited Amgen.
Sections with a free account
What changed this quarter
41 positions with a change (3 new, 16 added to, 20 trimmed, 2 sold); also, 1 exited through an acquisition or merger. 12 are listed here: those of 0.5 points of the portfolio or more (up to 12).
- Merck+459%more sharesIncreased7.4% → 6.5%
- Biogen+3.6 ppof portfolioNew— → 3.6%
- CVS Health+515%more sharesIncreased3.0% → 4.1%
- Eli Lilly−25%fewer sharesReduced8.7% → 9.6%
- AbbVie−41%fewer sharesReduced3.4% → 4.4%
- Intuitive Surgical−65%fewer sharesReduced3.0% → 2.6%
- Mirum Pharmaceuticals−49%fewer sharesReduced3.0% → 3.2%
- Revolution Medicines−88%fewer sharesReduced2.9% → 3.7%
- Amgen−2.3 ppof portfolioSold out2.8% → —
- Ionis Pharmaceuticals+392%more sharesIncreased3.0% → 2.9%
- Tango Therapeutics+564%more sharesIncreased1.2% → 1.7%
- Oruka Therapeutics+1.4 ppof portfolioNew— → 1.4%
The figure on the right: for positions added to or trimmed, the change in the number of shares (%); for new and sold ones, the points of the portfolio moved (pp). Below, the portfolio weight before → after. Traded weight: what it bought or sold, excluding price effects.
Top holdings
- Eli LillyLLY9.6%
- MerckMRK6.5%
- Johnson & JohnsonJNJ5.8%
- AbbVieABBV4.4%
- CVS HealthCVS4.1%
- Thermo Fisher ScientificTMO3.8%
- Revolution MedicinesRVMD3.7%
- BiogenBIIB3.6%
- Neurocrine BiosciencesNBIX3.3%
- Mirum PharmaceuticalsMIRM3.2%
- Alkermes plc.ALKS3.0%
- Ionis PharmaceuticalsIONS2.9%
- Beone MedicinesONC2.7%
- Intuitive SurgicalISRG2.6%
- StrykerSYK2.6%
“Since”: first quarter of the current run, unbroken until today. In the details, prices are the quarter-end prices of the quarters in which it added shares, per the 13F. The manager may have bought at any price within each quarter; the SEC only publishes the value at quarter end.
Portfolio by sector
- ● Health Care 100%
How its portfolio changed (8 quarters)
Q2 2026: 39
Q2 2026: 48%
Q2 2026: 26.7%
Traded turnover: the weight it bought plus the weight it sold in the quarter, divided by two, excluding price moves. The plain “turnover” in the header does include that effect. With a free account: the full history and sectors over time.
Stakes above 5% (13D/13G)
Companies where this filer reported holding 5% or more of the shares. It is the figure from its latest filing on each one; history since December 2024.
How we classify it
Type not verified. It meets the portfolio criteria of a concentrated manager, but its type is not verified: we found no official document that is enough to say what kind of entity it is. It may be an investment firm, but also an adviser adding up client accounts, a bank or a family vehicle. It counts in the tallies like the rest; keep that in mind when reading it. How the type is assigned
Managers of a similar size
A 13F portfolio value between a third and three times this one, whatever the type of filer. It is not a comparison of what they hold.
- M. Kraus$373M
- 3G Capital Partners$373M
- BruceInvestment firm · $369M
- RWC Asset Advisors (us)Investment firm · $377M
- Whetstone Capital AdvisorsInvestment firm · $377M
- Capco Asset ManagementInvestment firm · $366M